Located in Rockville, Maryland, Vigene Biosciences provides viral vector-based gene delivery services and products for research and clinical applications.
Vigene Biosciences, Inc. was founded in 2012 to provide services and products to support the rapidly growing field of gene therapy. At the time, adenovirus was the primary viral vector used, so Vigene developed cloning technologies to generate the largest collection of full-length human open reading frames packaged in adenovirus. Over the next few years, different viral vectors became more widely used for research, so Vigene expanded its viral packaging and cloning services to include the major viral vectors being used for gene delivery (AAV, adenovirus, lentivirus, and retrovirus). Vigene also diversified its product portfolio to include control viruses, shRNA clones, biosensors, and Parkinson’s disease tools. In 2016, Vigene acquired Omnia Biologics with its 15+ years of clinical manufacturing experience in response to the growing need for high titer, clinical-grade viral vectors as gene therapy candidates progressed to clinical trials. Since then, Vigene has continued to serve both research and clinical communities and has been recognized with national awards. In 2019, Vigene expanded into a new facility with 51,000 square feet and 10 new GMP suites to provide more opportunities for growth and innovation as the fields of gene and cell therapy continue to evolve.
2021 GMP production slots available! Contact us today for a free consultation >
Who We Are
We are a diverse and international team of molecular biologists, virologists, engineers, quality professionals, and supporting staff.
Who We Serve
We are proud to support scientists at any stage of research: from basic research, to animal studies, to clinical trials and commercialization. Our diverse customer base includes thousands of scientists all across the world from academia, government organizations, research institutes, biotechnology companies, and pharmaceutical companies.
To make gene therapy affordable.
To be the world’s leading viral gene delivery technology company.
Vigene ranked 410th and 81st on the Inc. 5000 list of fastest-growing private companies in America for 2019 and 2018, respectively. We were also named the 2018 ACG Emerging Company of the Year.